PETCT and MRI guided boost for prostate cancer radiotherapy
Phase 2
- Conditions
- Health Condition 1: C61- Malignant neoplasm of prostate
- Registration Number
- CTRI/2022/09/045258
- Lead Sponsor
- Varian Medical System
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1 Histological diagnosis of adenocarcinoma prostate
2 Suitableand planned for stereotactic body radiotherapy (SBRT) to the prostate
3 Visible DIL in both mpMRI and Ga68-PSMA PETCT scans done not more than four weeks apart
Exclusion Criteria
1 More than four weeks of androgen deprivation therapy or cancer-directed systemic therapy before baseline imaging
2 Inability to deliver adequate radiotherapy dose safely based on assessment by radiation oncologist
3 IPSS >20
4 Prior TURP within 3 months
5 Urethral stricture
6 Prostate gland volume >80cc
7 cT4 (AJCC 8th)
8 Untreated anal hemorrhoids/fissures
9 Pt unable to consent
10 Patients unwilling or unreliable for regular follow-up and surveillance imaging
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To measure the volumetric and spatial concordance between the DIL volume as delineated on the prostate multiparametric MRI (mpMRI) and RT planning Ga68-PSMA PETCT scansTimepoint: baseline radiotherapy planning
- Secondary Outcome Measures
Name Time Method To determine a suitable threshold for auto-contouring of the DIL volume in Ga68-PSMA PETCT <br/ ><br>Response assessment post radiotherapyTimepoint: Baseline radiotherapy planning, then every 3 months after completing radiotherapy, till total two years